These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27493216)

  • 41. Expression of dystroglycan, fukutin and POMGnT1 during mouse cerebellar development.
    Henion TR; Qu Q; Smith FI
    Brain Res Mol Brain Res; 2003 Apr; 112(1-2):177-81. PubMed ID: 12670716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glycosylation in congenital muscular dystrophies.
    Endo T; Toda T
    Biol Pharm Bull; 2003 Dec; 26(12):1641-7. PubMed ID: 14646163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
    Toda T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.
    Zhang P; Hu H
    Glycobiology; 2012 Feb; 22(2):235-47. PubMed ID: 21930648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss-of-function of an N-acetylglucosaminyltransferase, POMGnT1, in muscle-eye-brain disease.
    Manya H; Sakai K; Kobayashi K; Taniguchi K; Kawakita M; Toda T; Endo T
    Biochem Biophys Res Commun; 2003 Jun; 306(1):93-7. PubMed ID: 12788071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycosylation of α-dystroglycan: O-mannosylation influences the subsequent addition of GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases.
    Tran DT; Lim JM; Liu M; Stalnaker SH; Wells L; Ten Hagen KG; Live D
    J Biol Chem; 2012 Jun; 287(25):20967-74. PubMed ID: 22549772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy.
    Toda T; Kobayashi K; Takeda S; Sasaki J; Kurahashi H; Kano H; Tachikawa M; Wang F; Nagai Y; Taniguchi K; Taniguchi M; Sunada Y; Terashima T; Endo T; Matsumura K
    Congenit Anom (Kyoto); 2003 Jun; 43(2):97-104. PubMed ID: 12893968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RPTPζ/phosphacan is abnormally glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.
    Dwyer CA; Baker E; Hu H; Matthews RT
    Neuroscience; 2012 Sep; 220():47-61. PubMed ID: 22728091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mouse large can modify complex N- and mucin O-glycans on alpha-dystroglycan to induce laminin binding.
    Patnaik SK; Stanley P
    J Biol Chem; 2005 May; 280(21):20851-9. PubMed ID: 15788414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactive gliosis of astrocytes and Müller glial cells in retina of POMGnT1-deficient mice.
    Takahashi H; Kanesaki H; Igarashi T; Kameya S; Yamaki K; Mizota A; Kudo A; Miyagoe-Suzuki Y; Takeda S; Takahashi H
    Mol Cell Neurosci; 2011 Jun; 47(2):119-30. PubMed ID: 21447391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B4GAT1 is the priming enzyme for the LARGE-dependent functional glycosylation of α-dystroglycan.
    Praissman JL; Live DH; Wang S; Ramiah A; Chinoy ZS; Boons GJ; Moremen KW; Wells L
    Elife; 2014 Oct; 3():. PubMed ID: 25279697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthetic, structural, and biosynthetic studies of an unusual phospho-glycopeptide derived from α-dystroglycan.
    Mo KF; Fang T; Stalnaker SH; Kirby PS; Liu M; Wells L; Pierce M; Live DH; Boons GJ
    J Am Chem Soc; 2011 Sep; 133(36):14418-30. PubMed ID: 21812486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane.
    Yoshida-Moriguchi T; Campbell KP
    Glycobiology; 2015 Jul; 25(7):702-13. PubMed ID: 25882296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
    Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
    J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycosylation defects: a new mechanism for muscular dystrophy?
    Grewal PK; Hewitt JE
    Hum Mol Genet; 2003 Oct; 12 Spec No 2():R259-64. PubMed ID: 12925572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GTDC2 modifies O-mannosylated α-dystroglycan in the endoplasmic reticulum to generate N-acetyl glucosamine epitopes reactive with CTD110.6 antibody.
    Ogawa M; Nakamura N; Nakayama Y; Kurosaka A; Manya H; Kanagawa M; Endo T; Furukawa K; Okajima T
    Biochem Biophys Res Commun; 2013 Oct; 440(1):88-93. PubMed ID: 24041696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypoglycosylation of dystroglycan due to T192M mutation: a molecular insight behind the fact.
    Bhattacharya S; Das A; Ghosh S; Dasgupta R; Bagchi A
    Gene; 2014 Mar; 537(1):108-14. PubMed ID: 24361964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzymatic diagnostic test for Muscle-Eye-Brain type congenital muscular dystrophy using commercially available reagents.
    Zhang W; Vajsar J; Cao P; Breningstall G; Diesen C; Dobyns W; Herrmann R; Lehesjoki AE; Steinbrecher A; Talim B; Toda T; Topaloglu H; Voit T; Schachter H
    Clin Biochem; 2003 Jul; 36(5):339-44. PubMed ID: 12849864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cellular and molecular characterization of abnormal brain development in protein o-mannose N-acetylglucosaminyltransferase 1 knockout mice.
    Liu J; Yang Y; Li X; Zhang P; Qi Y; Hu H
    Methods Enzymol; 2010; 479():353-66. PubMed ID: 20816176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on alpha-dystroglycan.
    Hu Y; Li ZF; Wu X; Lu Q
    PLoS One; 2011 Feb; 6(2):e16866. PubMed ID: 21347376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.